Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
IBRX 
Immunitybio Inc (IBRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/18/2025: IBRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.4
1 Year Target Price $10.4
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -80.39% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/18/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.08B USD | Price to earnings Ratio - | 1Y Target Price 10.4 |
Price to earnings Ratio - | 1Y Target Price 10.4 | ||
Volume (30-day avg) 5 | Beta -0.06 | 52 Weeks Range 1.83 - 4.27 | Updated Date 12/18/2025 |
52 Weeks Range 1.83 - 4.27 | Updated Date 12/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -173.51% |
Management Effectiveness
Return on Assets (TTM) -36.89% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2362713527 | Price to Sales(TTM) 25.17 |
Enterprise Value 2362713527 | Price to Sales(TTM) 25.17 | ||
Enterprise Value to Revenue 28.62 | Enterprise Value to EBITDA -8.99 | Shares Outstanding 984965179 | Shares Floating 336375458 |
Shares Outstanding 984965179 | Shares Floating 336375458 | ||
Percent Insiders 66.41 | Percent Institutions 14.83 |
Upturn AI SWOT
Immunitybio Inc
Company Overview
History and Background
Immunitybio Inc. was founded in 2014 by Dr. Richard E. Gaynor and Dr. David L. Haig. The company is a late-stage immunotherapy company focused on developing novel therapies for cancer and other diseases. Significant milestones include its IPO in 2021 and ongoing clinical trials for its lead candidates.
Core Business Areas
- Oncology: Developing immunotherapies, particularly for cancer, utilizing a combination of cytokines, antibodies, and cell therapies. Their approach aims to activate the immune system to fight tumors.
- Infectious Diseases: Exploring the potential of their immunotherapy platform to treat viral infections, with a focus on conditions like HIV.
Leadership and Structure
Immunitybio Inc. is led by a management team with extensive experience in biotechnology and pharmaceutical development. The organizational structure is typical for a biotechnology company, with departments focused on research and development, clinical operations, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Product Name 1: N-803 (Anktiva) - A novel interleukin-15 (IL-15) superagonist complex. It is designed to stimulate the proliferation and survival of natural killer (NK) and T cells. In clinical trials, it has shown promise in treating BCG-unresponsive bladder cancer. Competitors in bladder cancer include Merck (Keytruda) and Astellas Pharma (Padcev).
- Product Name 2: ImmunoPulseu00ae IL-12 - A DNA-based immunotherapy designed to deliver IL-12 directly to tumor sites to activate the immune system. Competitors include other in-situ tumor immunotherapies and systemic immune-oncology drugs.
Market Dynamics
Industry Overview
The immunotherapy market, particularly in oncology, is a rapidly growing and highly competitive sector. Advancements in understanding the tumor microenvironment and immune checkpoints have led to a surge in research and development of novel therapies. The infectious disease immunotherapy space is also gaining traction.
Positioning
Immunitybio Inc. is positioned as an innovator in the immunotherapy space, focusing on differentiated approaches that combine multiple immune-modulating mechanisms. Their platform aims to address unmet needs in both oncology and infectious diseases, potentially offering advantages over single-modality treatments.
Total Addressable Market (TAM)
The global cancer immunotherapy market is projected to reach hundreds of billions of dollars in the coming years. The HIV immunotherapy market also represents a significant opportunity. Immunitybio Inc. is targeting specific indications within these large markets with its specialized therapies. Their positioning is focused on niche indications with high unmet needs where their platform can offer a distinct benefit.
Upturn SWOT Analysis
Strengths
- Proprietary immunotherapy platform with multiple drug candidates.
- Late-stage clinical development for key assets (e.g., N-803 in bladder cancer).
- Experienced leadership team in the biotechnology sector.
- Potential for combination therapies to enhance efficacy.
Weaknesses
- Reliance on clinical trial success for drug approval.
- Limited commercialization history and established revenue streams.
- Significant ongoing research and development costs.
- Potential for manufacturing and scalability challenges.
Opportunities
- Expanding clinical trials to other cancer types and indications.
- Partnerships and collaborations to accelerate development and commercialization.
- Leveraging their platform for infectious disease treatments.
- Potential for acquisitions by larger pharmaceutical companies.
Threats
- Intense competition in the immunotherapy market.
- Regulatory hurdles and the lengthy drug approval process.
- Failure of clinical trials leading to loss of investor confidence.
- Emergence of superior or more cost-effective therapies.
Competitors and Market Share
Key Competitors
- Merck & Co. (MRK)
- Astellas Pharma (ALPMY)
- Bristol Myers Squibb (BMY)
- Pfizer Inc. (PFE)
Competitive Landscape
Immunitybio Inc. faces intense competition from large pharmaceutical companies with established immunotherapy portfolios and significant resources. Its competitive advantage lies in its novel approach to immunotherapy, particularly its IL-15 superagonist and IL-12 platform, which may offer unique benefits in specific indications. However, it lags behind established players in terms of market penetration and commercial infrastructure.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Immunitybio Inc. has been characterized by the advancement of its pipeline through various stages of clinical development and securing funding through equity offerings.
Future Projections: Future projections are heavily contingent on the success of its ongoing clinical trials, particularly for N-803. Positive trial results and regulatory approvals would be the primary drivers of future growth. Analyst estimates would focus on potential peak sales for approved products and the overall market opportunity.
Recent Initiatives: Recent initiatives likely include the progression of clinical trials, strategic partnerships, and efforts to secure further funding to support pipeline development and potential commercialization.
Summary
Immunitybio Inc. is a promising clinical-stage immunotherapy company with a differentiated platform focused on oncology and infectious diseases. Its lead candidate, N-803, shows significant potential in bladder cancer. However, the company faces substantial risks associated with clinical trial outcomes, regulatory approvals, and intense competition in the rapidly evolving immunotherapy market. Successful execution of its clinical strategy and securing adequate funding will be critical for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Immunitybio Inc. official website
- SEC filings (10-K, 10-Q)
- Industry analysis reports
- Financial news and data providers
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence before making any investment decisions. Market share data is estimated and may vary based on different reporting methodologies and timeframes. Competitor and similar company lists are indicative and not exhaustive.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immunitybio Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-07-28 | President, CEO & Director Mr. Richard Gerald Adcock | ||
Sector Healthcare | Industry Biotechnology | Full time employees 673 | Website https://immunitybio.com |
Full time employees 673 | Website https://immunitybio.com | ||
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.